Sterling Capital Management’s Candel Therapeutics CADL Stock Holding History

Sterling Capital Management’s Portfolio CADL Stock Details CADL Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$1.82K	Sell	371 -139	-27%	-$756	﹤0.01%	3012
2025 Q4	$2.88K	Buy	510 +156	+44%	+$839	﹤0.01%	3015
2025 Q3	$1.8K	Buy	354 +192	+119%	+$1.11K	﹤0.01%	2996
2025 Q2	$820	Buy	162 +121	+295%	+$623	﹤0.01%	3088
2025 Q1	$232	Buy	41 +21	+105%	+$172	﹤0.01%	3068
2024 Q4	$174	Hold	20	–	–	﹤0.01%	3129
2024 Q3	$139	Buy	+20	New	+$124	﹤0.01%	3151

Other funds holding CADL

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

RTW Investments New York $10B AUM 135.35% 1-Year Est. Return

ACA

Acorn Capital Advisors New York $352M AUM 299.18% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

SVCM

Saturn V Capital Management Austin, Texas $552M AUM 551.78% 1-Year Est. Return

PCM

Portolan Capital Management Boston, Massachusetts $1.88B AUM 115.74% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

VPC

Vestal Point Capital New York $3.58B AUM 189.12% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Sterling Capital Management's CADL Position: Q1 2026 in Review

Sterling Capital Management reduced its Candel Therapeutics (CADL) stake by 27% in Q1 2026, selling an estimated $756 and leaving 371 shares worth $1.82K. The position accounts for ﹤0.01% of the portfolio, ranked #3012.

Sterling Capital Management first reported a position in CADL in Q3 2024 and has held it in 7 quarters since. The position peaked at $2.88K in Q4 2025. 114 funds tracked by Wall St. Rank hold CADL as of Q1 2026.

Sterling Capital Management held 371 shares of Candel Therapeutics worth $1.82K as of Q1 2026.
Sterling Capital Management sold 139 Candel Therapeutics shares in Q1 2026, an estimated $756.
Candel Therapeutics made up ﹤0.01% of Sterling Capital Management's portfolio in Q1 2026, its #3012 holding.
Sterling Capital Management first reported a position in Candel Therapeutics in Q3 2024 and has held it in 7 quarters since.
Sterling Capital Management's Candel Therapeutics position peaked at $2.88K in Q4 2025.
114 funds tracked by Wall St. Rank held Candel Therapeutics as of Q1 2026.

Based on Sterling Capital Management's 13F filing for Q1 2026, filed 22 Apr 2026.